The overall objective of the Center Pharmacogenomics of Statin Therapy (POST) is to apply genomic, transcriptomic, and metabolomic analyses, together with studies in cellular and animal models, and innovative informatic tools, to identify and validate biomarkers for efficacy of statin drugs in reducing riskof cardiovascular disease (CVD), and for adverse effects of statins, specifically myopathy and type 2 diabetes. This multidisciplinary approach is enabled by a team of investigators with expertise in genomics (human, mouse, and molecular), statistics and informatics, and clinical medicine and pharmacology. The Center is comprised of three Projects, two Research Cores, and an Administrative Core. A major aim of Project 1 is the identification of cellular transcriptomic and metabolomic markers for clinical efficacy and adverse effects of statins. This will be accomplished by analyses in statin-exposed lymphoblast cell lines derived from patients with major adverse coronary events, or onset of myopathy or type 2 diabetes on statin treatment, compared with unaffected statin- treated controls. In addition, using genome wide genotypes from these patients, DNA variants will be identified that are associated with statin-induced changes in the transcripts and metabolites that most strongly discriminate affected patients and controls. Project 2 will use a unique, well-characterized panel of 100 inbred mouse strains to discover genetic variation associated with statin-induced myopathy and dysglycemia. Mechanisms underlying these effects will be investigated, with emphasis on the role of dysregulation of autophagy by statin treatment. Projects 1 and 2 will also use relevant cellular and mouse models, respectively, to perform functional studies to validate effects of genes identified in all POST projects as strong candidates for modulating statin efficacy or adverse effects. In Project 3, information derived from genome-wide genotypes, electronic health records, and pharmacy data in a very large and diverse population-based patient cohort will be leveraged to identify and replicate genetic associations with statin efficacy (lipid lowering and CVD event reduction) and adverse effects (myopathy and type 2 diabetes), as well as to assess the overall heritability of these responses. The Clinical Core, based in Kaiser Permanente of Northern California, will provide the clinical information and biologic materials for both Projects1 and 3. Investigators in the Informatics Core will optimize data analysis and integration of results across all projects. The Administrative Core will provide scientific leadership and management of the Center, and foster scientific interactions and training opportunities. Overall, the research program of this Center provides an innovative model for a systems approach to pharmacogenomics that incorporates complementary investigative tools to discover and validate genetically influenced determinants of drug response. Moreover, the findings have the potential for guiding more effective use of statins for reducing CVD risk and minimizing adverse effects, and identifying biomarkers of pathways that modulate the multiple actions of this widely used class of drugs.

Public Health Relevance

Coronary heart disease and stroke are the leading causes of death and disability in the United States, and statins are the most widely prescribed class of drugs to prevent these conditions. There is however, considerable interindividual variation in efficacy of statins for reducing disease risk, as well as in susceptibility to the most common adverse statin effects, myopathy and type 2 diabetes. The goal of the Center 'Pharmacogenomics of Statin Therapy' (POST) is to apply complementary investigative approaches and multidisciplinary expertise for discovering and validating the genetic and metabolic factors responsible for this variability. This information has the potential for optimizig use of statins in clinical practice, and for identifying new pathways that underlie the diverse biologic actions of this drug class.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Specialized Center (P50)
Project #
5P50GM115318-04
Application #
9560840
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Long, Rochelle M
Project Start
2015-09-07
Project End
2020-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Children's Hospital & Res Ctr at Oakland
Department
Type
DUNS #
076536184
City
Oakland
State
CA
Country
United States
Zip Code
94609
Lee, Seung-Been; Wheeler, Marsha M; Patterson, Karynne et al. (2018) Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genet Med :
Kim, Dongwook; Shivakumar, Manu; Han, Seonggyun et al. (2018) Population-dependent Intron Retention and DNA Methylation in Breast Cancer. Mol Cancer Res 16:461-469
Miller, Jason E; Shivakumar, Manu K; Risacher, Shannon L et al. (2018) Codon bias among synonymous rare variants is associated with Alzheimer's disease imaging biomarker. Pac Symp Biocomput 23:365-376
Oni-Orisan, Akinyemi; Hoffmann, Thomas J; Ranatunga, Dilrini et al. (2018) Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. Circ Genom Precis Med 11:e002043
Orozco, Luz D; Farrell, Colin; Hale, Christopher et al. (2018) Epigenome-wide association in adipose tissue from the METSIM cohort. Hum Mol Genet 27:1830-1846
Kim, Kyungpil; Theusch, Elizabeth; Kuang, Yu-Lin et al. (2018) ZNF542P is a pseudogene associated with LDL response to simvastatin treatment. Sci Rep 8:12443
Veturi, Yogasudha; Ritchie, Marylyn D (2018) How powerful are summary-based methods for identifying expression-trait associations under different genetic architectures? Pac Symp Biocomput 23:228-239
Lee, Younghee; Han, Seonggyun; Kim, Dongwook et al. (2018) Genetic variation affecting exon skipping contributes to brain structural atrophy in Alzheimer's disease. AMIA Jt Summits Transl Sci Proc 2017:124-131
Hoffmann, Thomas J; Theusch, Elizabeth; Haldar, Tanushree et al. (2018) A large electronic-health-record-based genome-wide study of serum lipids. Nat Genet 50:401-413
El-Manzalawy, Yasser; Hsieh, Tsung-Yu; Shivakumar, Manu et al. (2018) Min-redundancy and max-relevance multi-view feature selection for predicting ovarian cancer survival using multi-omics data. BMC Med Genomics 11:71

Showing the most recent 10 out of 21 publications